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Abstract
Background. Incomplete control of troublesome regurgitation and extraesophageal manifestations of chronic
gastroesophageal reflux disease (GERD) is a known limitation of proton pump inhibitor (PPI) therapy. This multicenter
randomized study compared the efficacy of transoral incisionless fundoplication (TIF) against PPIs in controlling these
symptoms in patients with small hiatal hernias. Methods. Between June and August 2012, 63 patients were randomized
at 7 US community hospitals. Patients in the PPI group were placed on maximum standard dose (MSD). Patients in the
TIF group underwent esophagogastric fundoplication using the EsophyX2 device. Primary outcome was elimination of
daily troublesome regurgitation or extraesophageal symptoms. Secondary outcomes were normalization of esophageal
acid exposure (EAE), PPI usage and healing of esophagitis. Results. Of 63 randomized patients (40 TIF and 23 PPI), 3
were lost to follow-up leaving 39 TIF and 21 PPI patients for analysis. At 6-month follow-up, troublesome regurgitation
was eliminated in 97% of TIF patients versus 50% of PPI patients, relative risk (RR) = 1.9, 95% confidence interval
(CI) = 1.2-3.11 (P = .006). Globally, 62% of TIF patients experienced elimination of regurgitation and extraesophageal
symptoms versus 5% of PPI patients, RR = 12.9, 95% CI = 1.9-88.9 (P = .009). EAE was normalized in 54% of TIF
patients (off PPIs) versus 52% of PPI patients (on MSD), RR = 1.0, 95% CI = 0.6-1.7 (P = .914). Ninety percent of TIF
patients were off PPIs. Conclusion. At 6-month follow-up, TIF was more effective than MSD PPI therapy in eliminating
troublesome regurgitation and extraesophageal symptoms of GERD.
Keywords
transoral incisionless fundoplication (TIF), EsophyX, extraesophageal GERD symptoms, regurgitation, proton pump
inhibitor (PPI), heartburn

Introduction

1

Adequate control of troublesome regurgitation and extraesophageal manifestation such as laryngitis, asthma,
chronic cough, and dental erosions1 in chronic gastroesophageal reflux disease (GERD) patients remains a
therapeutic concern.2,3 Medical therapy with proton pump
inhibitors (PPIs) causes a modest and considerably less
symptomatic relief of regurgitation4 and extraesophageal
symptoms5-10 compared with heartburn. On the other
hand, despite its proven long-term effectiveness, laparoscopic Nissen fundoplication (LNF) is associated with
potential side effects such as gas bloat, dysphagia, and
uncontrolled flatulence.11 Additionally, failure of medical
therapy has been considered predictive of nonsatisfactory
outcomes of LNF.3 Recently, many attempts have been
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Table 1. Inclusion and Exclusion Criteria.
Inclusion Criteria

Exclusion Criteria

Age: 18-80 years
Gastroesophageal reflux disease duration: >1
year
History of daily proton pump inhibitors (PPIs)
use >6 months
Troublesome atypical symptoms and/or
regurgitation (with or without heartburn) while
on daily PPI therapy
Abnormal 48-hour pH off PPIs (total % time
pH < 4 > 5.3%)
Hill grade I or II
Willingness to undergo pH testing
Willingness to adhere to postoperative diet
for 6 weeks

Availability for follow-up visits
Willingly and cognitively signed informed
consent

Body mass index (BMI) >35 kg/m2
Hiatal hernia >2 cm in axial length and/or >2 cm in greatest transverse
dimensions
Esophagitis grade C or D; Barrett’s esophagus >2 cm; esophageal ulcer; fixed
esophageal stricture or narrowing
Portal hypertension and/or varices
Active gastroduodenal ulcer disease
Gastroparesis, gastric outlet obstruction, or stenosis
Coagulation disorder
History of any of the following: resective gastric or esophageal surgery,
antireflux surgery with anatomy unsuitable for transoral incisionless
fundoplication (TIF) procedure per physician judgment, cervical spine
fusion, Zenker’s diverticulum, esophageal epiphrenic diverticulum, achalasia,
scleroderma ordermatomyositis, eosinophilic esophagitis, or cirrhosis
Pregnancy or plans of pregnancy in the 12 months following treatment
Enrollment in another device or drug study that may confound the results

made to develop an alternative and less invasive treatment that would bridge the gap between medical therapy
and LNF.
Several retrospective and prospective studies have
reported that transoral incisionless fundoplication (TIF)
performed with EsophyX device (EndoGastric Solutions,
Redmond, WA) is capable of improving GERD symptoms and patient satisfaction of those suffering from
chronic GERD when the associated hiatal hernia defect is
small (≤2 cm).12 A notable absence of randomized studies
evaluating the procedure has prevented a better definition
of its role in the management of chronic GERD.13
The TEMPO trial (TIF EsophyX vs Medical PPI Open
Label Trial) compared the efficacy of the TIF procedure
against maximal dose PPI therapy in controlling regurgitation and extraesophageal symptoms of GERD in
patients who partially responded to PPIs. The primary
hypothesis was that TIF would be more effective than
PPIs in eliminating daily troublesome regurgitation or
extraesophageal GERD symptoms at 6-month follow-up.
The secondary hypotheses were that the majority of TIF
patients would normalize their esophageal acid exposure
(EAE) compared with baseline and that the majority of
TIF patients would be completely off PPIs.

Methods
Study Design
This multicenter, open label, randomized, comparative
study was conducted at 7 study sites in the United States.

The institutional review board of the participating institutions approved the study protocol. Written consent was
obtained from all patients before randomization after all
critical information about the study had been explained in
detail. Patients who had met the eligibility criteria were
randomly assigned to receive either TIF or maximum
dose PPI therapy with a target allocation ratio of 2:1.
There were no important changes to methods after study
initiation and no interim analyses for efficacy were
performed.

Patients
Patients experiencing persistent daily troublesome regurgitation or extraesophageal GERD symptoms (with or
without heartburn) on daily PPIs were deemed eligible
for the study if they had documented abnormal EAE as
determined by ambulatory 48-hour pH monitoring while
off PPI therapy for at least 7 days (% total time pH < 4
occurred for >5.3% of the recording time14) and hiatal
hernia measurements not exceeding 2 cm in both axial
length and in greatest transverse dimension. A complete
list of inclusion and exclusion criteria is presented in
Table 1. Eligible patients were randomly assigned to
receive either TIF or maximum standard dose (MSD) PPI
therapy. Patients in the PPI group were required to take
the MSD of currently used PPI in an attempt to optimize
control of their GERD symptoms. The same brand of PPI
used by individual patients at screening was prescribed
by investigators at the maximal allowed dose per manufacturer’s recommendations and provided free of charge

Downloaded from sri.sagepub.com at GEORGE WASHINGTON UNIVERSITY on May 1, 2014

3

Trad et al
Table 2. Baseline Characteristics of Study Patients.a
Characteristics

TIF Group (n = 39)

PPI Group (n = 21)

20 (51)
54.8 (35.7-73.3)
14 (36)
20 (51)
5 (13)
28.9 (20.5-34.9)
10 (2-50)
7 (1-25)
1 (3)
20 (51)
1 (5)
19 (95)
37 (95)
5 (14)
32 (86)
36 (92)
14 (39)
22 (61)

13 (62)
50.1 (32.5-63.3)
10 (48)
11 (52)
0 (0)
28.3 (24.5-34.9)
10 (1-20)
8 (1-22)
0 (0)
13 (62)
4 (31)
9 (69)
18 (86)
2 (11)
16 (89)
16 (76)
3 (19)
13 (81)

Female, n (%)
Age in years, median (range)c
< 50, n (%)
50-65, n (%)
> 65, n (%)
Body mass index, kg/m2, median (range)c
GERD symptom duration in years, median (range)c
PPI therapy duration in years, median (range)c
Barrett’s esophagus, <2 cm, n (%)
Esophagitis (Los Angeles grade), n (%)
A, n (%)
B, n (%)
Hill grade, n (%)
I, n (%)
II, n (%)
Hiatal hernia, n (%)
Axial length ≤1cm, n (%)
Axial length >1cm and ≤2 cm, n (%)
GERD Health-Related Quality of Life score, median (range)
On PPIsc
Off PPIsc
Heartburn score, median (range)
On PPIsc
Off PPIsc
Reflux Symptom Index score, median (range)
On PPIsc
Off PPIsc
Reflux Disease Questionnaire score, median (range)
On PPIsc
Off PPIsc
Total % time pH < 4, median (range)1
Patients on single dose of PPI at entry, n (%)
Patients on Omeprazole at entry, n (%)
Patients on Esomeprazole at entry, n (%)
Patients on Lansoprazole at entry, n (%)
Patients on Pantoprazole at entry, n (%)
Patients on Dexlansoprazole at entry, n (%)

P Valuesb
.587
.206
.418
>.999
.152
.871
.586
.861
>.999
.587
.066
.066
.332
>.999
>.999
.114
.208
.208

27 (4-48)
34 (7-50)

26 (16-39)
34 (21-49)

.896
.536

19 (4-30)
23.5 (4-30)

17 (7-27)
24 (16-30)

.560
.733

23 (3-43)
25 (2-42)

23 (4-35)
27 (17-42)

.774
.211

3.2 (0-5)
3.9 (0.6-5.0)
9.6 (5.4-19.5)
27 (69)
16 (41)
9 (23)
5 (13)
6 (15)
3 (8)

3.4 (0.3-4.0)
4.0 (2.3-5.0)
9.3 (5.4-17.2)
16 (76)
10 (48)
8 (38)
1 (5)
1 (5)
1 (5)

.721
.191
.636
.765
.785
.243
.412
.404
>.999

Abbreviations: TIF, transoral incisionless fundoplication; PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease.
a
Hill grade and esophagitis were evaluated with screening endoscopy. Of 12 patients in the TIF group who were taking double-dose PPIs at entry,
6 (50%) patients were on Omeprazole, 3 (25%) on Pantoprazole, 2 (17%) on Lansoprazole, and 1 (8%) on Esomeprazole. In the PPI group, of 5
patients who were taking double-dose PPIs, 3 (60%) patients were on Esomeprazole and 2 (40%) were on Omeprazole.
b
P values were calculated using 2-tailed Fisher exact test unless indicated otherwise.
c
Mann–Whitney U test.

to each patient randomized to the PPI group. A complete
listing of PPI brands used in this study is provided in
Table 2. Patients in the TIF group underwent endoscopic
fundoplication using the latest iteration of the EsophyX2
device to perform the standardized TIF-2.0 protocol previously described elsewere.15,16 In brief, under general
anesthetic, the EsophyX device was gently introduced
over the flexible endoscope into the stomach under constant endoscopic visualization. The helical retractor was

engaged into the tissue slightly distal to Z line. Then, in
combination with the tissue manipulating elements, the
fundus of the stomach was folded up and around the distal esophagus. After tissue handling elements were appropriately positioned and locked into place, the invaginator
was activated to allow the separation of the gastroesophageal junction from the diaphragm. The polypropylene
“H” fasteners were delivered through the tissue. The
same maneuvers were repeated at 3 additional positions
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to create full thickness, partial, gastroesophageal fundoplication. TIF patients were generally discharged 24
hours postprocedure and were asked to follow the standard dietary and physical restrictions previously
described.15 Patients were evaluated and followed in
community-based practices by clinical teams led by 4
surgeons and 3 gastroenterologists. TIF procedures were
performed in the associated community hospitals.

Preprocedure Evaluation
All patients enrolled in the study underwent thorough
preprocedure evaluation, including complete history,
physical examination, symptom assessment, esophagogastroduodenoscopy (EGD), and 48-hour pH monitoring.
Gastroesophageal manometry was performed in selected
patients to rule out diagnoses of achalasia or severe
esophageal dysmotility disorders, whenever warranted
by clinical suspicion. In some cases, a barium swallow
was obtained to further evaluate esophageal anatomy and
esophageal clearance and to rule out any suspected
esophageal structural problems.
All patients underwent two screening visits (Figure 1).
During the first screening visit, demographic characteristic of study patients, frequency, dose, and duration of
GERD medication usage were collected while patients
were on currently used PPIs. Symptom assessment was
carried out using three validated GERD-specific instruments: (a) Gastroesophageal Health-Related Quality of
Life (GERD-HRQL), (b) Reflux Symptom Index (RSI),
and (c) Reflux Disease Questionnaire (RDQ). Patients
who suffered from daily troublesome GERD symptoms
other than heartburn, such as atypical GERD symptoms
or regurgitation while taking daily PPIs were eligible to
undergo further testing. These patients were asked to discontinue PPI therapy for 7 days and to return for the second screening visit.
Symptom assessment was repeated off PPI therapy for
7 days during the second screening visit using the same
questionnaires. All patients underwent EGD and 48-hour
pH test off PPIs to objectively confirm the diagnosis of
GERD. EGD was used to confirm the presence of esophagitis, assess the size of hiatal hernia, and evaluate the
appearance of gastroesophageal junction using Hill grade
classification. Biopsies were performed whenever indicated by the findings at endoscopy. A 48-hour pH test was
performed after discontinuation of PPIs for 7 days. Per
protocol, EAE was considered abnormal if % total time
pH <4 occurred for >5.3% of the recording time.14

Follow-up Evaluation
Three follow-up visits were scheduled (2 weeks, 3 months,
and 6 months) for all patients. Postprocedure symptoms,

adverse events, and medication usage for all patients were
recorded at all follow-up visits. Patients in the TIF group
were required to completely discontinue PPI usage 14
days after the procedure and to follow the postprocedure
diet for a total of 6 weeks.
At the 6-month follow-up visit, patients in the PPI
(control) group completed the GERD-HRQL, RSI, and
RDQ questionnaires and underwent EGD and 48-hour
pH monitoring while on MSD PPIs. Patients in the TIF
group completed the same 3 questionnaires and tests
6 months postprocedure while off PPIs. In addition, the
minority of patients in the TIF group who had resumed
taking PPIs 6 months postprocedure were asked to complete the same questionnaires while on PPI therapy.

Study End Points and Efficacy Assessments
The primary endpoint was elimination of daily troublesome
GERD symptoms other than heartburn as evaluated by
GERD-HRQL, RSI, and RDQ instruments at 6-month follow-up. GERD-HRQL is designed and validated to evaluate typical GERD symptoms by measuring 10 items
(6 related to heartburn, 2 to dysphagia, 1 to bloating, and 1
to the impact of medications on daily life) on the visual analog scale ranging from 0 (no symptoms) to 5 (worst symptoms).17 A higher total GERD-HRQL score (range from 0 to
50) indicates more severe GERD.15 RSI is a 9-item validated questionnaire used to measure atypical GERD symptoms such as hoarseness, throat clearing, excess throat
mucus, dysphagia, and cough.18 The scale for each individual item ranges from 0 (no problem) to 5 (severe problem),
with a maximum total score of 45 and a normality threshold
of ≤13.18 RDQ is a 12-item questionnaire that was designed
to assess the frequency and severity of heartburn (4 items
measuring the frequency and severity of pain and burning
behind the breastbone), regurgitation (4 items measuring
the frequency and severity of acid taste in the mouth and
movement of the material upward from the stomach), and
dyspeptic complaints (4 items measuring the frequency and
severity of pain or burning in the upper stomach).19
Response options range from 0 (not present) to 5 (daily) for
frequency and 0 (not present) to 5 (severe) for severity.
Each patient’s score is calculated as the mean of item
responses with higher scores indicating more severe or frequent symptoms.19 In the current study, elimination of daily
troublesome symptoms was defined as a score ≤2 on the
GERD-HRQL and RSI questionnaires; in the case of RDQ,
elimination of moderate to severe regurgitation with the frequency reduced to 1 day a week or less (this corresponds to
scores of ≤2 for frequency and severity of regurgitation).
The RSI questionnaire was used to assess atypical GERD
symptoms while RDQ was used to assess regurgitation.
GERD-HRQL was used to assess heartburn, bloating, and
satisfaction with current health condition.
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Figure 1. Screening assessments of study patients.

Secondary efficacy endpoints were normalization of
EAE, healing of esophagitis, and PPI use. Complete discontinuation of PPI therapy was considered clinically significant for TIF patients.

In addition to primary and secondary endpoints,
patient satisfaction, incidence of de novo postfundoplication symptoms (bloating, excess flatulence, and dysphagia) and serious adverse events were documented.

Downloaded from sri.sagepub.com at GEORGE WASHINGTON UNIVERSITY on May 1, 2014

6

Surgical Innovation 

Sample Size and Randomization
An unequal randomization allocation of 2:1 was chosen
primarily to reduce the costs associated with this trial. A
sample size of n = 42 (28 TIF, 14 PPI) was needed for an
80% power to detect a significant difference (α of .05)
between the 2 groups. The power calculation was based
on the assumption that >70% of the patients randomized
to the TIF group would have their daily troublesome
symptoms eliminated compared with ≤20% in the PPI
group. To account for eventual attrition due to loss of
follow-up and individual patient refusal to undergo EGD
or 48-hour pH monitoring at follow-up, 12 more patients
were allocated to TIF group and 9 more patients were
allocated to PPI group (n = 63; 40 TIF, 23 PPI). Using a
random number generator software, an independent statistician established the randomization sequence in blocks
of 9 with stratification according to participating centers.
Patient assignment was provided to participating centers
via sealed opaque envelopes, and was concealed from
clinical staff and patients during the 2 screening visits.
The envelopes with randomization were opened after the
second screening visit, in the presence of patients who
had met all the eligibility criteria.

Statistical Analysis
Data were collected on a 37-page case report form and
then transferred to a study specific and secured electronic
database (FileMaker Pro 10, Santa Clara, CA). The
Shapiro–Wilk test was used for normality testing.
Continuous, normally distributed data were presented as
the mean ± standard deviation (SD). Data with skewed
distribution were reported as the median (range). Fisher
exact test was used to determine the significance of 2 × 2
contingency tables. Unadjusted relative risk (RRs) and
95% confidence intervals (CIs) were calculated to estimate the relative effect of TIF as compared with that of
PPI therapy for all outcomes. Two-tailed Mann–Whitney
U test was used to assess the difference between nonparametric data. The P values for changes at follow-up compared with those at baseline within the same treatment
group were calculated using the 2-tailed paired t test or
the Wilcoxon signed rank test; in case of proportions,
McNemar’s test was used. A P value of less than .05 was
considered significant. Statistical analyses were performed using JMP 10.0 software.

Results
Baseline Characteristics of the Patients
Between June and August 2012, 63 patients were randomized into the study; 40 patients into the TIF group
and 23 patients into the PPI group. All randomized

patients had abnormal distal esophageal acid exposure.
The flowchart of screened, enrolled, and analyzed patients
is shown in Figure 2. The treatment groups were well
matched at entry (Table 2). There were no differences
between treatment groups in the clinical features of the
disease, such as duration of symptoms, duration of PPI
use before procedure and/or severity of the disease based
on symptom score and abnormal acid exposure as
expressed in % time pH < 4. Overall, a slight majority of
patients were female (33 of 63, 52%) and only 5 of 63
patients (8%) were older than 65 years. Medication dosage and PPIs used before randomization are shown in
Table 2.

Safety and Procedure Outcomes
All TIF procedures were performed under general anesthesia and were completed successfully without conversion to open or laparoscopic approaches. In 37 of 39
(95%) cases no related issues with the EsophyX2 device
were reported. In one case, the anterior wire used to transfer fasteners from the cartridge to a stylet was damaged,
leading the physician to complete procedure with the posterior wire only. In another case, the gastric distention
was suboptimal, making the procedure technically more
challenging. The average time required to complete the
procedure, measured from device introduction to removal,
was 38 minutes (range = 20-68 minutes, SD = 14 minutes). On average, 21 (range = 16-30, SD = 4) contributing fasteners were used to create an esophagogastric
fundoplication with a mean length of 2.8 cm (range =
2.5-4 cm, SD = 0.5 cm) and a circumference of 290°
(range 240° to 340°, SD = 18°) as evaluated by immediate postprocedure endoscopy. All 31 patients who were
assigned a preprocedure Hill grade II were converted to
Hill grade I. Postoperative valve adherence to the endoscope was tight in 79% (31/39) and moderate in 21%
(8/39) of patients. All 36 hiatal hernias present at screening were reduced. Ninety-eight percent of patients were
discharged within 24 hours. Two patients (5%) stayed in
the hospital for 2 days; one for the management of postoperative dizziness and nausea and one because of allergic reaction to pain medication. There were no reports of
any serious adverse event or hospital readmission associated with the TIF procedure.

Primary Outcome
Troublesome regurgitation, as evaluated by RDQ questionnaire, was eliminated in 97% (29/30) of patients in
the TIF group (off PPIs) versus 50% (9/18) of patients in
the PPI group (on MSD), RR = 1.9, 95% CI = 1.2-3.1
(P < .001). Elimination of atypical GERD symptoms
such as throat clearing, troublesome or annoying cough,
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Figure 2. CONSORT flowchart of study patients.

Abbreviations: PPIs, proton pump inhibitors; TIF, transoral incisionless fundoplication.

and hoarseness is charted in Figure 3. Globally, at
6-month follow-up, complete elimination of all daily
troublesome GERD symptoms other than heartburn was
observed in 62% (24/39) of patients in the TIF group
compared with 5% (1/21) in the PPI group, RR = 12.9,
95% CI = 1.9-88.9 (P < .001).

Secondary Outcomes
Proton Pump Inhibitor Use. All patients in the TIF group
were on daily PPI therapy before enrollment and randomization. At 6-month follow-up, 90% (35/39, 95% CI =
0.76-0.97) of patients in the TIF group had completely
stopped taking PPIs; 3% (1/39, 95% CI= <.0001 to 0.14)

of patients were taking PPIs on demand and 8 % (3/39,
95% CI = 0.02-0.21) were back on daily PPIs (Figure 3).
Out of the 3 patients who were back on daily PPIs, 1 had
reduced the original dose and 2 patients were on a higher
dose. Of the 4 patients who were back on some form of
PPI therapy, 1 remained dissatisfied with current health
condition compared with 4 dissatisfied before TIF. Before
enrollment in this study, of these 4 patients, 2 used PPIs
for >20 years, one patient was on PPIs for 18 years and 1
was taking PPIs for 7 years. Two of these 4 patients
reported PPI use at 3-month follow-up; another 2 patients
started taking the PPIs after 3-month follow-up visit. Of
these 4 patients, 1 had normalized distal esophageal acid
exposure (% total time pH < 4 was reduced from 9.9 to
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Figure 3. (A) Elimination of daily troublesome atypical symptoms as evaluated by RSI questionnaires at 6-month follow-up. (B)
PPI use before TIF and at 6-month follow-up. (C) Quality-of-life scores in patients back on some form of PPI regimen. (D) Rate of
healing or reduction of reflux esophagitis in both treatment arms. (E) Elimination of daily troublesome heartburn as evaluated by
GERD-HRQL questionnaires.
Abbreviations: GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPIs, proton pump inhibitors; RDQ, Reflux Disease
Questionnaire; RSI, Reflux Symptom Index; TIF, transoral incisionless fundoplication.
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Table 3. Changes in Mean 48-Hour pH Parameters From Before Treatments to 6-Month Follow-Up in Both Treatment Groups.
pH Parameters
Number of refluxes
Number of long refluxes (>5 minutes)
Duration of longest reflux, minutes
Fraction time pH < 4, %
DeMeester score

TIF group (n = 39);
Difference in Means (95% CI)

P Valuesa

−59.9 (−80.7 to −39.2
−4.1 (−6.1 to −2.0)
−7.9 (−15.6 to −0.3)
−3.4 (−4.9 to −1.9)
−11.6 (−17.4 to −5.9)

<.001
<.001
.042
<.001
<.001

PPI group (n = 21);
Difference in Means (95% CI)
−99.1 (−133.7 to −64.5)
−7.9 (−10.9 to −4.9
−2.7 (−13.3 to 7.9)
−5.5 (−7.4 to −3.6)
−16.5 (−23.0 to −10.0)

P Valuesa
<.001
<.001
.598
<.001
<.001

Abbreviations: PPI, proton pump inhibitor; TIF, transoral incisionless fundoplication; CI, confidence interval.
a
P values were calculated with paired t test.

Table 4. Changes in Mean Symptom Scores in Patients With Abnormal Distal Esophageal Acid Exposure From Before
Treatments to 6-Month Follow-up in Both Treatment Groups.
Questionnaires/
Symptoms
GERD-HRQL score
Heartburn score
Regurgitation score
RDQ score
RSI score

TIF Group (n = 18);
Difference in Means (95% CI)

P Valuesa

PPI Group (n = 10);
Difference in Means (95% CI)

P Values

−17.9 (−25.8 to −10.1)
−12.2 (−18.1 to −6.3)
−2.9 (−3.5 to −2.2)
−2.7 (−3.3 to −2.0)
−15.3 (−20.3 to −10.3)

<.001
<.001
<.001
<.001
<.001

−3.6 (−9.6 to 2.4)
−2.6 (−5.7 to 0.5)
−0.7 (−1.4 to 0)
−0.7 (−1.5 to 0.1)
−1.3 (−6.3 to 3.7)

.206
.090
.042
.071
.574

Abbreviations: GERD-HRQL, gastroesophageal reflux disease health-related quality of life; RDQ, Reflux Disease Questionnaire; RSI, Reflux
Symptom Index; PPI, proton pump inhibitor; TIF, transoral incisionless fundoplication.
a
P values were calculated using paired t test.

3.1), 1 had improved (from 8.3 to 6.7), and 2 experienced
increase in % total time pH < 4 (from 16.8 to 23.2 and
from 15.7 to 22.2). Quality of life scores in patients back
on PPIs are shown in Figure 3.

Objective Outcomes
In the TIF group, 54% (21/39) of patients had normalized
esophageal acid exposure (off PPIs) compared to 52%
(11/21) of patients on maximum dose PPI in the control
group, RR = 1.0, 95% CI = 0.6-1.7 (P = .914). A significant reduction of all 48-hour pH Bravo parameters was
achieved in the TIF group; PPI therapy did not reach significant reduction in the duration of the longest reflux
episode (Table 3). Of patients with abnormal acid exposure at 6 months postprocedure, 11% (2/18) in the TIF
group were dissatisfied with their current health condition versus 100% dissatisfied (10/10) in the PPI group,
RR = 0.13, 95% CI = 0.05-0.42 (P < .001). The reduction
in the total GERD-HRQL, RSI, and RDQ scores in
patients with abnormal esophageal acid exposure at
6-month follow-up is shown in Table 4.
Endoscopic Assessment. All patients underwent endoscopic evaluation at 6-month follow-up. Complete healing or reduction in reflux esophagitis at 6 months was

achieved in 90% (18/20) of patients in the TIF group (off
PPIs) compared with 38% (5/13) in PPI group (on MSD),
RR = 2.3, 95% CI = 1.2-4.7 (P = .018; Figure 3). Hiatal
hernias remained reduced in all patients (36/36) who had
a hiatal hernia before the TIF procedure. The valve
appearance was judged as a Hill grade I in all cases. One
patient who had short segment Barrett’s (<2 cm) before
the procedure was found to have healed esophageal erosions. This patient was off PPIs at 6-month follow-up and
% total time pH < 4 was reduced from 9 before procedure
to 1.5 at 6-month follow-up.

Ancillary Analyses
Heartburn, Patient Satisfaction, and Quality of Life. Ninety
percent (28/31) of patients in the TIF group (off PPIs)
reported elimination of daily troublesome heartburn versus
13% (2/16) of patients in the PPI group (maximum daily
dose); RR = 7.2, 95% CI = 2.0-26.6 (P = .003; Figure 3).
The median heartburn score in the TIF group, as
evaluated by the GERD-HRQL questionnaire, improved
significantly falling from 19 (range = 4-30) on PPIs
before TIF to 2 (range = 0-26) off PPIs at 6-month follow-up (P < .001); in the PPI group the median heartburn score also improved, decreasing from 17 (range =
7-27) on screening to 11 (range = 0-27) on maximum
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PPI dose (P = .012). Figure 4 charts the progression of
individual heartburn scores for all study patients from
pretreatment values to 6-month follow-up. The median
total GERD-HRQL score in the TIF group improved
significantly from 27 (range = 4-48) on PPIs before TIF
to 4 (range = 0-33) off PPIs at 6-month follow-up (P <
.001); in the PPI group, the median total GERD-HRQL
score also significantly improved from 26 (range =
16-39) to 19 (range = 2-42) on maximum PPI dose (P =
.009).
Patient satisfaction with current health condition, as
evaluated by GERD-HRQL, improved significantly in
the TIF group compared with baseline on PPIs (72%
[28/39] satisfied while off PPIs vs 3% [1/39] satisfied
before TIF while on PPIs [P < .001]). In the PPI group,
patient satisfaction did not improve significantly (5%
[1/21] satisfied while on maximum PPI dose vs 0% [0/21]
satisfied at screening [P > .999]). Between-group analysis revealed significantly more patients in the TIF group
(72%, 28/39) were satisfied with their current health condition after treatment compared with PPI group (5%,
1/21), RR = 15.1, 95% CI = 2.2-103.1 (P = .006).
Satisfaction with current health condition is charted in
Figure 4.
The median total RSI score in the TIF group decreased
significantly from 23 (range = 0-43) on PPIs before procedure to 3 (range = 0-25) off PPIs at 6-month follow-up
(P < .001). A minor improvement in the median total RSI
score in the control group on MSD PPI therapy did not
reach statistical significance (from 23 [range = 4-35] at
screening to 21 [range = 6-32] [P = .205]). Individual RSI
scores are shown in Figure 4.
The median total RDQ score in the TIF group was significantly decreased from 3.2 (range = 0-5) before TIF on
PPIs to 0.2 (range = 0-2.4) off PPIs at 6-month follow-up
(P < .001); the median total score for the regurgitation
component of the RDQ questionnaire also significantly
improved from 3.2 (range = 0-5) to 0 (range = 0-1.3; P <
.001). In the PPI group, the median total RDQ score significantly improved declining from 3.4 (range = 0.3-4.0)
to 2.0 (range = 0.3-4.1; P < .001); however, the median
total regurgitation score was insignificantly improved
from 3.0 (range = 0.3-5.0) to 2.5 (range = 0.5-4.3) at
6-month follow-up on maximum daily PPI dose (P =
.111).
Dysphagia, Bloating, and Flatulence. Twelve of 39 (31%)
patients in the TIF group and 8 of 21 (38%) patients in the
PPI group suffered from daily troublesome dysphagia at
screening (score >2). The elimination of daily troublesome dysphagia was experienced in 92% (11/12) of
patients in the TIF group compared to 75% (6/8) in the
PPI group, RR = 1.2, 95% CI = 0.8-1.9 (P = .366). In the
TIF group, 1 patient reported worsening dysphagia (score

from 1 to 4); in the PPI group, 2 patients reported worsening (score from 1 to 3 and score from 2 to 3). There were
no reports of de novo dysphagia in either group. Bloating
was improved in 79% (19/24) of patients in the TIF
group, compared with 25% (4/16) in the PPI group, RR =
3.2, 95% CI = 1.3-7.6 (P = .009). There were no reports
of de novo bloating in either group. In the TIF group, of 5
patients who reported daily troublesome bloating at 6
month follow-up, 3 improved slightly (scores from 4 to 3)
and 2 patients reported unchanged severity of bloating
(scores 3 to 3 and scores 5 to 5); in the PPI group, of 12
patients who reported daily troublesome bloating at
6-month follow-up, 3 patients reported unchanged symptoms and 9 patients reported worsening of bloating. Seventeen of 21 patients (81%) in the TIF group and 2 of 12
(17%) in the PPI group reported elimination of daily
troublesome flatulence at 6-month follow-up, RR = 4.9,
95% CI = 1.3-17.5; P = .016). There were no reports of de
novo troublesome flatulence in either group.

Discussion
The 3 major findings of this multicenter randomized
study comparing TIF to maximum dose PPIs in a select
group of patients with chronic GERD and hiatal hernias
measuring less than 2 cm were as follows: (a) TIF was
more effective than PPIs in elimination of troublesome
regurgitation, (b) a majority of TIF patients (90%) were
completely off PPIs at 6-month follow-up, and (c) TIF
was equivalent to PPIs in normalizing distal EAE. To the
best of our knowledge, this is the first time that an endoscopic anti-reflux procedure involving reconstruction of
the gastroesophageal junction, was found to be more
effective than PPIs in controlling troublesome typical and
atypical GERD symptoms.20-22
The study population in both group consisted of
patients who were partial responders to PPI therapy, as
indicated by lower QOL scores on PPIs compared with
the QOL scores off PPIs at screening (Table 2). We chose
to use MSD PPI as the control group because patients suffering ongoing symptoms despite medical therapy are
routinely stepped up to maximum dosage in an attempt to
control troublesome symptoms. Methodologically this
design is justified by the fact that more than two thirds of
patients were not on MSD at time of enrollment (Table 2).
Patients with persistent symptoms despite MSD PPI therapy choosing to undergo traditional surgical therapy11
may face an additional risk to develop persistent postfundoplication symptoms (gas bloat, dysphagia, and inability to belch) suggesting that this population is left with
limited treatment options. In contrast, as confirmed with
present study, current published literature on TIF suggests that incidence of persistent postfundoplication side
effects is low after TIF.12
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Figure 4. (A) Patient satisfaction with current health condition as evaluated by GERD-HRQL questionnaire. (B) Individual
total GERD-HRQL scores in all patients before treatments and at 6-month follow-up. (C) Individual total heartburn scores in
all patients before treatments and at 6-month follow-up. (D) Individual total RSI scores in all patients before treatments and at
6-month follow-up.
Abbreviations: GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPIs, proton pump inhibitors; RSI, reflux symptom
index; TIF, transoral incisionless fundoplication. Red lines represent improvement in the mean scores.
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The study was conducted by general surgeons (4 centers) and gastroenterologists (3 centers) acting as investigators and device operators. This mix was intentional to
eliminate a specialty bias. The similarity of outcomes
achieved by investigators across specialties is encouraging and suggests that the TIF procedure can be performed
equally well by both foregut surgeons and gastroenterologists with advanced endoscopic skills.
The Montreal consensus defined regurgitation as the
perception of flow of refluxed gastric content into the
mouth or hypopharynx.1 Troublesome symptoms are
defined as mild symptoms occurring 2 or more days a
week, or moderate to severe symptoms occurring more
than 1 day a week.1 Control of troublesome regurgitation
is viewed in the current literature as the principal shortcoming of PPI therapy.2 Kahrilas et al4 concluded that
PPIs caused a modest and considerably less symptomatic
relief of regurgitation compared with heartburn. In our
study, troublesome regurgitation was eliminated in 97%
of patients in the TIF arm when compared with 50% in
the PPI group when MSD were administered. This difference suggests that rebuilding the mechanical and geometrical characteristics of the gastroesophageal valve is
important when attempting to control symptoms potentially arising from proximal extend of the refluxate. This
study confirms the previously reported outcomes with
regards to elimination of regurgitation15,23,24 and suggests
that TIF could be an alternative treatment option for this
subgroup of patients.
Review of the literature yields success rates for LNF
in eliminating troublesome extraesophageal symptoms
ranging between 48% and 65%.25-27 In this study, TIF was
significantly more effective than MSD PPIs (Figure 3) in
eliminating throat clearing (83% vs 23%), troublesome or
annoying cough (83% vs 13%), and hoarseness (92% vs
20%). We believe that patients with extraesophageal
symptoms achieved positive results because of the fact
that they had objective evidence of GERD, and had relatively small anatomic defects. TIF could be considered a
viable alternative for the patient population with a significant extraesophageal component provided that the same
inclusion criteria are used in clinical practice.
Beyond the clinical relevance of the major findings of
this study related to TIF, we found that MSD of PPIs were
not better than TIF in eliminating heartburn, healing of
reflux esophagitis, and normalizing distal EAE. We speculate that the unexpectedly low rate of healing of esophagitis in the PPI group (38%) may indicate that a higher
proportion of patients in this study suffered from nonacid reflux or weakly acid reflux. The published data on
the normalization of EAE after PPI treatment are limited.14 Milkes et al28 reported that 50% of patients had
persistent abnormal EAE despite taking PPIs twice daily.
Our study reproduces these results in the PPI group.

Although we performed a medication count and it appears
that patients complied with their prescribed medical regimens, we recognize that full control of patients’ compliance is difficult to achieve. Therefore, we cannot discount
the possibility that some patients did not comply with
prescribed medications influencing the rate of EAE normalization in the control group.
In the TIF group, significant symptoms control (up to
97%) was not followed by the similar rate of pH normalization (54%). Improvement in patient quality of life and
healing of esophagitis are often cited as the goals of treatments for GERD, and accordingly are often the endpoints
of many studies related to GERD therapies.15 The level of
esophageal acid exposure in patients who were asymptomatic on PPI therapy is poorly addressed in the literature. Among 4 studies we found, 17% to 80% of patients
demonstrated abnormal esophageal acid exposure while
being asymptomatic on PPI therapy.29-32 As this matter
relates to newer technologies for GERD, Bell et al15 did
not find association between symptomatic outcomes and
normalization of esophageal acid exposure after TIF, mirroring findings from another study.33 Future studies
involving pH impedance may better define the relationship between symptomatic outcomes and normalization
of esophageal acid exposure post TIF and further elucidate the effects of TIF and PPIs in patients with nonacid
reflux.
Patients in the TIF group had a significant improvement in every 48-hour pH parameter, but did not reach
the levels of pH normalization reported for laparoscopic
fundoplication.34 It has been argued that the higher rates
of pH normalization reported post–laparoscopic fundoplication result from the creation of a “supercompetent”
gastroesophageal valve, which may also cause postfundoplication side effects such as dysphagia (11%), bloating (40%), diarrhea (16%), and flatulence (57%) in a
significant number of patients at 5-year follow-up.11 Such
occurrences result in patient dissatisfaction, additional
health care and societal costs and the need for revisional
procedures or endoscopic esophageal dilatations in cases
of severe persistent dysphagia. In this study, none of the
patients in the TIF group reported de novo bloating, dysphagia, or flatulence at 6-month follow-up. Although, the
comparison of postfundoplication symptoms after the
TIF procedure and after LNF is based on different time
intervals, we believe that the very limited incidence of
side effects combined with a solid safety record (no
reported mortality in more than 13 000 cases performed
worldwide) represents one of the most attractive aspects
of TIF procedure.
The only patient with short segment Barrett’s in this
trial was randomized to the TIF group and was completely off PPIs with a normalized distal esophageal
exposure at 6-month follow-up. The role of TIF in the
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management of Barrett’s metaplasia remains to be defined
and will no doubt require additional studies. This patient
will be kept under strict endoscopic surveillance.
Our findings must be interpreted while considering the
limitations of this study, most notably the short-term follow-up and the potential placebo effect in the TIF group.
We felt that reporting these encouraging short-term
results is reasonable given that the recommended treatment for patients with predominant extraesophageal
symptomatology is aggressive acid reduction using PPIs
twice daily short-term over a duration of 3 to 4 months.35
To address the potential placebo effect, another randomized trial which includes a sham arm is currently underway with early results expected in the near future. One
may argue that the small sample size (39 in the TIF group
vs 21 in the PPI group) and unequal randomization allocation could affect our findings. In this context, it is worth
pointing that the use of unequal randomization ratios will
only significantly reduce the power of the study if a ratio
of 3:1 or more is used.36 Furthermore, the study has been
appropriately powered (80%) to detect significant differences between the 2 treatment arms. A further potential
limitation of this study was that the study population was
heterogeneous with regards to predominant symptomatology; we feel that this is reflective of the fact that specialized GERD practices are increasingly evaluating and
treating patients with mixed symptomatology. And
finally, we used randomization and objective pH testing
to minimize potential bias from an open-label study
design. To further minimize this bias, all PPI patients
were offered crossover to TIF after completion of 6-month
follow-up. We will report these outcomes as results
become available.
With regard to predictors of success or failures following TIF, a critical analysis of the 4 patients who continued acid suppressive medication after TIF revealed
important findings. As previously suggested,15 our study
also demonstrates that patients with more severe disease
appear to have a higher likelihood of requiring PPIs after
TIF. All 4 patients suffered from severe heartburn
(GERD-HRQL scores >30 on PPIs). Although 10% of
patients were back on PPI therapy, the significant
improvement in the QOL scores postprocedure (Figure
3) suggests that TIF may be a useful therapeutic adjunct
to PPIs in patients with incomplete symptom control. We
attempted to define factors predictive of post-treatment
normalization of esophageal acid exposure. The fact that
all patients in the study underwent pH testing at screening and at 6-month follow-up presented a unique opportunity to define these factors. We observed that
preprocedure % total time pH < 4 inferior to 10 was
associated with a high rate of pH normalization after TIF
(74% [17/23] normalized vs 25% [4/12] normalized if %
time pH < 4 was ≥10; [P = .004]). Interestingly, the same

observation could not be made in the PPI group (66%
normalized [8/12] if % time pH < 4 was inferior to 10
before vs 33% [3/9] if % time was ≥10 after taking maximal PPI dose for 6 months [P = .198]). Beyond the previously defined factors associated with successful
outcomes such as hiatal hernia ≤2 cm and GERD-HRQL
<30, this study suggests that preprocedure total % time
pH < 4 inferior to 10 could be an important factor in
selecting the most appropriate patients and setting appropriate expectations for the TIF procedure in individual
cases. We plan to report a comprehensive evaluation of
factors associated with successful outcomes after TIF at
a longer term follow-up. Also, in this study, we reported
our results in terms of complete elimination of troublesome symptoms and pH normalization over 48 hours
rather than ≥50% reduction in total scores and % total
time pH < 4 based on 24 hours. We believe that these
stricter and more comprehensive evaluation criteria may
provide a useful reference in assessing patients for less
invasive GERD therapies.
Based on the results of this study, it would appear that
the TIF procedure is ideally suited as a treatment alternative for GERD patients who fall in the so-called “therapy
gap,” a term often used to describe the 30% to 40% of
patients who take daily PPIs and who remain unsatisfied
because of incomplete symptom control.3 These patients
are often unwilling to undergo a laparoscopic fundoplication for fear of its side effects. TIF may offer these
patients the opportunity to safely eliminate their troublesome typical and atypical symptoms without the risk of
developing postfundoplication syndromes.

Conclusion
In conclusion, among select patients presenting with persistent troublesome GERD symptoms and small hiatal
hernias (≤2 cm), TIF, compared to maximal standard dose
PPI therapy, resulted in better control of regurgitation and
a wide range of chronic GERD symptoms while avoiding
the undesirable postfundoplication syndromes associated
with laparoscopic antireflux procedure in some patients.
Patients in the TIF and PPI arms were found to have similar rates of distal esophageal pH normalization. Despite
encouraging results from this study, longer term followups are warranted.
Acknowledgments
The authors thank Emir Deljkich, MD, for his assistance with
this research.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of
interest with respect to the research, authorship, and/or publication of this article: Dr Trad and Dr Simoni have reported that

Downloaded from sri.sagepub.com at GEORGE WASHINGTON UNIVERSITY on May 1, 2014

14

Surgical Innovation 

they have a consulting agreement with EndoGastric Solutions.
Dr Trad, Dr Barnes, Dr Simoni, Dr Shughoury, Dr Mavrelis,
Dr Raza, Dr Heise, Dr Turgeon, and Dr Fox reported that their
institutions have received grant for research from EndoGastric
Solutions for pre- and postoperative testing, TIF procedure,
medications, and support for study coordinator.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded in total by EndoGastric Solutions,
Inc, Redmond, Washington.

References
1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R;
Global Consensus Group. The Montreal definition and
classification of gastroesophageal reflux disease: a
global evidence-based consensus. Am J Gastroenterol.
2006;101:1900-1920.
2. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in
primary care and community studies. Aliment Pharmacol
Ther. 2010;32:720-737.
3. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease.
Am J Gastroenterol. 2013;108:308-328.
4. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitaion to proton pump inhibitir therapy in clinical trials
of gastroesophageal reflux disease. Am J Gastroenterol.
2011;106:1419-1425.
5. Chan WW, Chiou E, Obstein KL, Tignor AS, Whitlock
TL. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med.
2011;171:620-629.
6. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske
LA. Gastro-oesophageal reflux treatment for prolonged
non-specific cough in children and adults. Cochrane
Database Syst Rev. 2011;19:CD004823.
7. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump
inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am
J Gastroenterol. 2006;101:2646-2654.
8. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of
omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study.
Laryngoscope. 2001;111:2147-2151.
9. Steward DL, Wilson KM, Kelly DH, et al. Proton pump
inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck
Surg. 2004;131:342-350.
10. Vaezi MF, Richter JE, Stasney CR, et al. Treatment
of chronic posterior laryngitis with esomeprazole.
Laryngoscope. 2006;116:254-260.
11. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic
antireflux surgery vs esomeprazole treatment for chronic
GERD: the LOTUS randomized clinical trial. JAMA.
2011;305:1969-1977.

12. Wendling MR, Melvin WS, Perry KA. Impact of transoral
incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published
literature. Surg Endosc. 2013;27:3754-3761.
13. Society of American Gastrointestinal and Endoscopic
Surgeons (SAGES). Endoluminal treatments for gastroesophageal reflux disease (GERD). http://www.sages.org/
publication/id/CSR1/. Accessed December 8, 2013.
14. Hirano I, Richter JE, Practice Committee of the American
College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol.
2007;102:668-685.
15. Bell RC, Mavrelis PG, Barnes WE, et al. A prospective
multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. J Am Coll Surg. 2012;215:794-809.
16. Bell RC, Cadiere GB. Transoral rotational esophago-gastric fundoplication: technical, anatomical, and safety consideration. Surg Endosc. 2011;25:2387-2399.
17. Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus
MA. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg. 1996;183:217-224.
18. Belafsky PC, Postma GN, Koufman JA. Validity and
reliability of the reflux symptom index (RSI). J Voice.
2002;16:274-279.
19. Shaw M, Talley NJ, Beebe T, et al. Initial validation of a
diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:52-57.
20. Coron E, Sebille V, Cadiout G, et al. Clinical trial: radiofrequency energy delivery in proton pump inhibitor-dependent
gastro-oesophageal reflux disease patients. Aliment Pharmacol
Ther. 2008;28:1147-1158.
21. Comay D, Adam V, da Silveira EB, Kennedy W, Mayrand
S, Barkun AN. The Stretta procedure versus proton pump
inhibitors and laparoscopic Nissen fundoplication in the
management of gastroesophageal reflux disease: a costeffectiveness analysis. Can J Gastroenterol. 2008;22:552558.
22. Parker M, Smith CD. Comparing the effectiveness of
endoscopic full-thickness plication and endoscopic radiofrequency treatments for patients with GERD. Expert Rev
Gastroenterol Hepatol. 2010;4:387-390.
23. Trad KS, Turgeon DG, Deljkich E. Long-term outcomes
after transoral incisionless fundoplication in patients with
GERD and LPR symptoms. Surg Endosc. 2012;26:650660.
24. Bell RC, Freeman KD. Clinical and pH-metric outcomes
of transoral esophago-gastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc.
2011;25:1975-1984.
25. Oelschlager BK, Eubanks TR, Oleynikov D, Pope C,
Pellegrini CA. Symptomatic and physiologic outcomes
after operative treatment for extraesophageal reflux. Surg
Endosc. 2002;16:1032-1036.
26. Duffy JP, Maggard M, Hiyama DT, et al. Laparoscopic
Nissen fundoplication improves quality of life in patients
with atypical symptoms of gastroesophageal reflux. Am
Surg. 2003;69:833-838.

Downloaded from sri.sagepub.com at GEORGE WASHINGTON UNIVERSITY on May 1, 2014

15

Trad et al
27. Wright RC, Rhodes KP. Improvement of laryngopharyngeal reflux symptoms after laparoscopic Hill repair. Am J
Surg. 2003;185:455-461.
28. Milkes D, Gerson LB, Triadafilopoulus G. Complete elimination of reflux symptoms does not guarantee normalization
of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol.
2004;99:991-996.
29. Sarela AI, Hick DG, Verbeke CS, Casey JF, Guillou PJ,
Clark GW. Persistent acid and bile reflux in asymptomatic
patients with Barrett esophagus receiving proton pump
inhibitor therapy. Arch Surg. 2004;139:547-551.
30. Oritz A, Martínez de Haro LF, Parrilla P, Molina J, Bermejo
J, Munitiz V. 24-hour pH monitoring is necessary to assess
acid reflux suppression in patients with Barrett’s oesophagus undergoing treatment with proton pump inhibitors. Br
J Surg. 1999;86:1472-1474.
31. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization

32.

33.

34.

35.

36.

of intraesophageal acid reflux in patients with Barrett’s
esophagus. Am J Gastroenterol. 1998;93:711-716.
Katzka DA, Castell DO. Successful elimination of reflux
symptoms does not insure adequate control of acid reflux
in patients with Barrett’s oesophagus. Am J Gastroenterol.
1994;89:989-991.
Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the health-related
quality of life and physiologic parameters. Am Surg.
1998;64:649-653.
Stefanidis D, Hope WW, Kohn GP, et al. Guidelines for
surgical treatment of gastroesophageal reflux disease. Surg
Endosc. 2010;24:2647-2669.
Richter JE. Review article: extraesophageal manifestations
of gastroesophageal reflux disease. Aliment Pharmacol
Ther. 2005;22(suppl 1):70-80.
Dumville JC, Hahn S, Miles JN, Torgerson DJ. The use
of unequal randomization ratios in clinical trials: a review.
Contemp Clin Trials. 2006;27:1-12.

Downloaded from sri.sagepub.com at GEORGE WASHINGTON UNIVERSITY on May 1, 2014

